Open AccessProtamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo
Author(s) -
Jesse M. Young,
Amira Zine El Abidine,
Ricardo Gómez-Martínez,
Virginie Bondu,
Rosa T. Sterk,
Zurab Surviladze,
Michelle A. Ozbun
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01513-21
Subject(s) - hpv infection , protamine sulfate , in vivo , immunology , protamine , virology , virus , biology , medicine , cervical cancer , cancer , heparin , microbiology and biotechnology
Human papillomavirus (HPV) infections are transmitted through sexual or other close contact and are etiologically associated with epithelial warts, papillomas, and intraepithelial lesions that may progress to cancer. Indeed, 4.8% of the global cancer burden is linked to HPV infection.